Cocrystal Pharma, Inc. (COCP) financial statements (2021 and earlier)

Company profile

Business Address 19805 N. CREEK PARKWAY
BOTHELL, WA 98011
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7679357
Cash and cash equivalents7679357
Restricted cash and investments0000000
Receivables1111   
Other undisclosed current assets0000000
Total current assets:87910357
Noncurrent Assets
Operating lease, right-of-use asset1111
Property, plant and equipment0000000
Intangible assets, net (including goodwill)19656565656565
Goodwill19656565656565
Deposits noncurrent assets0000   
Other undisclosed noncurrent assets    05454
Total noncurrent assets:2066666666119119
TOTAL ASSETS:2973757669124126
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2211111
Accounts payable21101  
Accrued liabilities00010  
Employee-related liabilities00000  
Other undisclosed accounts payable and accrued liabilities     11
Debt00000  
Deferred rent credit    0  
Derivative instruments and hedges, liabilities0000000
Total current liabilities:2222211
Noncurrent Liabilities
Long-term debt and lease obligation11110  
Finance lease, liability0000
Capital lease obligations0  
Operating lease, liability1111
Liabilities, other than long-term debt     1213
Deferred rent credit     00
Deferred tax liabilities, net 1213
Total noncurrent liabilities:111101213
Total liabilities:332221314
Stockholders' equity
Stockholders' equity attributable to parent2671727467111113
Common stock0000000
Additional paid in capital261258258258254254254
Accumulated deficit(235)(187)(186)(184)(187)(143)(141)
Total stockholders' equity:2671727467111113
TOTAL LIABILITIES AND EQUITY:2973757669124126

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:0015   
Operating expenses(48)(2)(2)(2)(56)(2)(2)
Operating income (loss):(48)(2)(2)3(56)(2)(2)
Nonoperating income (expense)0000(0)0(0)
Interest and debt expense   (0)(0)  
Other undisclosed income from continuing operations before equity method investments, income taxes   00 0
Income (loss) from continuing operations before income taxes:(48)(2)(2)3(56)(2)(2)
Income tax benefit    1201
Net income (loss) available to common stockholders, diluted:(48)(2)(2)3(44)(2)(1)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(48)(2)(2)3(44)(2)(1)
Comprehensive income (loss), net of tax, attributable to parent:(48)(2)(2)3(44)(2)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: